MedTrace Logo

An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.

NCT03029988 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2020-09-10

Study results available
· View outcomes & findings →

Summary

Estimation of the concordance of Tc 99m localization in liver metastases from colorectal carcinoma using SPECT/CT imaging and abdominal FDG (PET)/CT imaging per subject.

Conditions

  • Liver Metastases
  • Colorectal Carcinoma

Interventions

DRUG

Tilmanocept (Technetium Tc 99m tilmanocept Injection)

Drug: Technetium Tc 99m tilmanocept

PROCEDURE

SPECT/CT Imaging

4-6 hours post-injection SPECT/CT will be obtained in the abdominal region.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • Navidea Biopharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Frederick O Cope, PhD · Navidea Biopharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-26
Primary Completion
2018-09-24
Completion
2018-09-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03029988 on ClinicalTrials.gov